Pharsight

Mounjaro is owned by Eli Lilly And Co.

Mounjaro contains Tirzepatide.

Mounjaro has a total of 4 drug patents out of which 0 drug patents have expired.

Mounjaro was authorised for market use on 13 May, 2022.

Mounjaro is available in solution;subcutaneous dosage forms.

Mounjaro can be used as mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Drug patent challenges can be filed against Mounjaro from 2026-05-13.

The generics of Mounjaro are possible to be released after 14 June, 2039.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9474780	ELI LILLY AND CO	GIP and GLP-1 co-agonist compounds	Jan, 2036 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Feb, 2031 (7 years from now)
US9402957	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Jun, 2031 (8 years from now)
US11357820	ELI LILLY AND CO	GIP/GLP1 agonist compositions	Jun, 2039 (16 years from now)

Do you want to check out MOUNJARO patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 13, 2027

NCE-1 date: 2026-05-13

Market Authorisation Date: 13 May, 2022

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS